A molecular approach for identifying individuals with Li-Fraumeni syndrome who have a limited family history

Clinical Genetics

Volumn 75, Issue 3, 2009, Pages 294-297

  Ang, P ^a,b   Lim, I H K ^a   Yong, R Y Y ^c   Lee, Ann S G ^a,d  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b GLENEAGLES HOSPITAL   (Singapore)

^c DSO NATIONAL LABORATORIES   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE LKB1; PROTEIN P53;

BREAST CANCER; CANCER RISK; CODON; FAMILIAL CANCER; FAMILY HISTORY; FRAMESHIFT MUTATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HUMAN; LETTER; MOLECULAR DYNAMICS; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADULT; AMINO ACID SEQUENCE; BASE SEQUENCE; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA MUTATIONAL ANALYSIS; FAMILY; FEMALE; HUMANS; LI-FRAUMENI SYNDROME; MOLECULAR SEQUENCE DATA; MUTATION;

EID: 60549102889     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2008.01133.x     Document Type: Letter

References (29)

1. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969: 71: 747-752.
2. Malkin D, Li FP, Strong LC et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990: 250: 1233-1238.
3. Varley JM. Germline TP53 mutations and Li-Fraumeni syndrome. Hum Mutat 2003: 21: 313-320.
4. Rodier F, Campisi J, Bhaumik D. Two faces of p53: Aging and tumor suppression. Nucleic Acids Res 2007: 35: 7475-7484.
5. Evans DG, Birch JM, Thorneycroft M, McGown G, Lalloo F, Varley JM. Low rate of TP53 germline mutations in breast cancer/sarcoma families not fulfilling classical criteria for Li-Fraumeni syndrome. J Med Genet 2002: 39: 941-944.
6. Birch JM, Hartley AL, Tricker KJ et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994: 54: 1298-1304.
7. Bang YJ, Kang SH, Kim TY et al. The first documentation of Li-Fraumeni syndrome in Korea. J Korean Med Sci 1995: 10: 205-210.
8. Kim IJ, Kang HC, Shin Y et al. A TP53-truncating germline mutation (E287X) in a family with characteristics of both hereditary diffuse gastric cancer and Li-Fraumeni syndrome. J Hum Genet 2004: 49: 591-595.
9. Miller RW. The U.S.-Japan Cooperative Cancer Research Program: Some highlights of seminars, interdisciplinary program area, 1981-1996. Jpn J Cancer Res 1996: 87: 221-226.
10. Yamada H, Shinmura K, Okudela K et al. Identification and characterization of a novel germ line p53 mutation in familial gastric cancer in the Japanese population. Carcinogenesis 2007: 28: 2013-2018.
11. Ang P, Lim IH, Lee TC et al. BRCA1 and BRCA2 mutations in an Asian clinic-based population detected using a comprehensive strategy. Cancer Epidemiol Biomarkers Prev 2007: 16: 2276-2284.
12. Lopez-Guerrero JA, Pellin A, Noguera R, Carda C, Llombart-Bosch A. Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors. Lab Invest 2001: 81: 803-814.
13. Lee AS, Ang P. CHEK2*1100delC screening of Asian women with a family history of breast cancer is unwarranted. J Clin Oncol 2008: 26: 2419; author reply 2419-2420.
14. Petitjean A, Mathe E, Kato S et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat 2007: 28: 622-629.
15. Koduru PR, Raju K, Vadmal V et al. Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. Blood 1997: 90: 4078-4091.
16. Sepehr A, Taniere P, Martel-Planche G et al. Distinct pattern of TP53 mutations in squamous cell carcinoma of the esophagus in Iran. Oncogene 2001: 20: 7368-7374.
17. Simms LA, Radford-Smith G, Biden KG et al. Reciprocal relationship between the tumor suppressors p53 and BAX in primary colorectal cancers. Oncogene 1998: 17: 2003-2008.
18. Breton J, Sichel F, Abbas A, Marnay J, Arsene D, Lechevrel M. Simultaneous use of DGGE and DHPLC to screen TP53 mutations in cancers of the esophagus and cardia from a European high incidence area (Lower Normandy, France). Mutagenesis 2003: 18: 299-306.
19. Pu CE, Linacre A. Systematic evaluation of sensitivity and specificity of sibship determination by using 15 STR loci. J Forensic Leg Med 2008: 15: 329-334.
20. Tzeng CH, Lyou JY, Chen YR et al. Determination of sibship by PCR-amplified short tandem repeat analysis in Taiwan. Transfusion 2000: 40: 840-845.
21. Ang P, Garber JE. Genetic susceptibility for breast cancer - risk assessment and counseling. Semin Oncol 2001: 28: 419-433.
22. Vahteristo P, Bartkova J, Eerola H et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002: 71: 432-438.
23. Szabo CI, King MC. Population genetics of BRCA1 and BRCA2. Am J Hum Genet 1997: 60: 1013-1020.
24. Neuhausen SL. Ethnic differences in cancer risk resulting from genetic variation. Cancer 1999: 86: 2575-2582.
25. Lim W, Hearle N, Shah B et al. Further observations on LKB1/STK11 status and cancer risk in Peutz-Jeghers syndrome. Br J Cancer 2003: 89: 308-313.
26. Hearle N, Schumacher V, Menko FH et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 2006: 12: 3209-3215.
27. Mills GB, Lu Y, Fang X et al. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol 2001: 28: 125-141.
28. Evans DG, Birch JM, Ramsden RT, Sharif S, Baser ME. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: Substantial risks in certain tumour prone syndromes. J Med Genet 2006: 43: 289-294.
29. Burke W, Press N. Genetics as a tool to improve cancer outcomes: Ethics and policy. Nat Rev Cancer 2006: 6: 476-482.